Panacos Pharmaceuticals, Inc.
Panacos Announces Preliminary Results of Bevirimat Study 204
Published in AIDS Weekly, November 10th, 2008
Panacos Pharmaceuticals, Inc. (NASDAQ: PANC) announced the bevirimat Study 204 achieved its primary objective by demonstrating bevirimat plasma levels in HIV-positive patients to be in a target range for virologic reduction. Bevirimat is a novel HIV-1 Gag maturation inhibitor in Phase 2b testing, and the data from the successful completion of this study will be used to optimize the bevirimat tablet dose for future Phase 2 as well as Phase 3 registration trials.
After 14 days of bevirimat treatment given twice daily at doses of 200mg or 300mg (using the 50mg tablet), 100% of 32 treatment-naive and treatment-experienced patients in Study 204 had bevirimat plasma...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2008-11-10)
More Articles from AIDS Weekly
- Johns Hopkins University Bloomberg School of Public Health
Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults - Epstein-Barr Virus
Researchers from University of Pennsylvania provide details of new studies and findings in the area of Epstein-Barr virus - HIV/AIDS Co-Infection
Data from C.E. French et al provide new insights into HIV/AIDS co-infection - HIV/AIDS Co-Infection
Findings from M.L. Grijsen and co-researchers advance knowledge in HIV/AIDS co-infection - HIV/AIDS Co-Infection
New findings from University of London in the area of HIV/AIDS co-infection published - HIV/AIDS Co-Infection
Reports outline HIV/AIDS co-infection study findings from C.G. Meyer and colleagues - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
